CRP and diabetes mellitus: The therapy with this drug not only lowered the level of pro-inflammatory markers such as C-reactive protein (CRP) or TNF-α, but also increased levels of anti-inflammatory cytokines which ultimately led to reduce the inflammation in the blood serum of patients with diabetes.